AZD0120
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Pressure score
62
Momentum score
20
Why This Matters
Bristol Myers Squibb is a direct competitive threat because it has a Phase III program in Hematology · Multiple Myeloma (AZD0120) and could narrow AstraZeneca's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Competitor is materially ahead in development and could reach market before the signal asset.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb document relevant to the signal.
Source: Bristol Myers Squibb
View source documentRelated Signal
AstraZeneca's AZD0120 Phase I Study in Multiple Myeloma Initiated
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 3
Bristol Myers Squibb
1 competitive finding
Top program: AZD0120
- Pressure
- 62
- Momentum
- 20
- Threat
- direct competitor
- Stage
- Phase III
62Bristol Myers SquibbMediumAZD0120·Phase III
Pfizer
1 competitive finding
Top program: AZD0120
- Pressure
- 60
- Momentum
- 14
- Threat
- emerging competitor
- Stage
- Phase I
60PfizerMediumAZD0120·Phase I
Roche
2 competitive findings
Top program: AZD0120
- Pressure
- 54
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
54RocheMediumAZD0120·Approved